Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk ICU admission 10% c19early.org/c Simsek et al. Vitamin C for COVID-19 LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 139 patients in Turkey Lower mortality with vitamin C (not stat. sig., p=0.19) Simsek et al., Annals of Medical Research, doi:10.5455/annalsmedres.2020.10.1043 Favors vitamin C Favors control
Effects of high dose vitamin C administration in Covid-19 patients
Simsek et al., Annals of Medical Research, doi:10.5455/annalsmedres.2020.10.1043
Simsek et al., Effects of high dose vitamin C administration in Covid-19 patients, Annals of Medical Research, doi:10.5455/annalsmedres.2020.10.1043
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 139 hospitalized patients in Turkey, 58 treated with high dose vitamin C, showing improved kidney functioning with treatment. Mortality was lower with treatment, but not reaching statistical significance with the small sample size.
risk of death, 44.1% lower, RR 0.56, p = 0.18, treatment 6 of 58 (10.3%), control 15 of 81 (18.5%), NNT 12.
risk of ICU admission, 10.2% lower, RR 0.90, p = 0.66, treatment 18 of 58 (31.0%), control 28 of 81 (34.6%), NNT 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Simsek et al., 27 Sep 2021, retrospective, Turkey, peer-reviewed, 16 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Ann Med Res 2021;28(9):1699-703 Annals of Medical Research Original Article DOI: 10.5455/annalsmedres.2020.10.1043 Effects of high dose vitamin C administration in Covid-19 patients Fatih Simsek1, Hasan Yonca2, Irmak Tahmaz3, Umut Kara1, Ender Sir1, Sami Eksert1, Mehmet Emin Ince1, Serkan Senkal1, Ilker Ozdemirkan1, Ufuk Turan1, Umit Savascı2, Deniz Dogan4, Canturk Tasci4, Ertugrul Yazici2, Gulden Yilmaz2, Ahmet Cosar1 Department of Anesthesiology and Reanimation, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey Department of Infectious Diseases and Clinical Microbiology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey 3 Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey 4 Department of Pulmonology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey 1 2 Copyright@Author(s) - Available online at www.annalsmedres.org Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Abstract Aim: There is currently no pharmacotherapy with for the treatment of COVID-19. We aimed to investigate the effects of early and high-dose vitamin C (VC) therapy in hospitalized patients with COVID-19. Materials and Methods: We included patients (n=139) who received high-dose VC supplement to the standard treatment protocol into group 1 (n=58), and only those who received a standard treatment protocol into group 2 (n=81). The patients' requirement for supplemental oxygen therapy, requirement for intensive care treatment and survival rates was investigated retrospectively. Furthermore, the changes in white blood cell, C-reactive protein (CRP), procalcitonin, D-Dimer, renal function tests, ferritin, and interleukin 6 values during hospitalization were evaluated. Results: When the groups were compared in terms of clinical data, there was no significant difference in terms of the patients requiring supplemental oxygen therapy (p=0.808), requiring intensive care (p=0.662), and survival rates (p=0.185). However, a significant difference was observed between the groups in terms of changes in renal function tests, and CRP values (p<0.05). Conclusion: In the present study, early administration of high-dose VC to patients with COVID-19 has a reducing effect on the impaired kidney functions. Therefore, we recommend the use of VC as an early supplemental therapy in patients with COVID-19. Keywords: Ascorbic acid; coronavirus; kidney function tests; severe acute respiratory syndrome; pneumonia
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit